Portfolio news .

Abliva

Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study

Oxford Nanopore Technologies Plc

Oxford Nanopore Technologies plc - Appoints Two Non-Executive Directors

Ultraleap Ltd

Ultraleap and Prophesee enter into a strategic partnership to provide industry-first hand tracking on event sensors for AR devices

C-Capture Ltd

C-Capture Announces Successful Start to Europe’s First Carbon Capture Trial in the Flat Glass Industry

Abliva

Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354

Mission Therapeutics Limited

Mission Therapeutics announces US FDA approval to initiate Phase II clinical trial of its lead asset MTX652 in Acute Kidney Injury

Accelercomm Ltd

AccelerComm Expands LDPC Accelerator IP Licenses for 5G Cloud RAN High-Capacity Solutions

Diffblue Ltd

Diffblue Announces Citi as a Strategic Investor

Storm Therapeutics

STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference

Oxford Nanopore Technologies Plc

Oxford Nanopore Technologies - Nanopore Community Meeting Technology Update